ADMA Biologics (ADMA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
15 Apr, 2026Voting matters and shareholder proposals
Election of two Class I directors, Alison C. Finger and Eduardo Rene Salas, for terms expiring at the 2029 annual meeting or until successors are elected and qualified.
Ratification of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Advisory vote to approve compensation of named executive officers.
Other business may be addressed if properly brought before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of all proposals, including director elections and auditor ratification.
Executive compensation and say-on-pay
Advisory vote scheduled to approve, on a non-binding basis, the compensation of named executive officers.
Partial view of Summaries dataset, powered by Quartr API
Latest events from ADMA Biologics
- ASCENIV drove margin and earnings growth as BIVIGAM declined sharply amid IG market headwinds.ADMA
Q1 20266 May 2026 - Virtual annual meeting to vote on directors, auditor, and executive pay, with Board support.ADMA
Proxy filing15 Apr 2026 - 2025 revenue up 20% to $510M, with 2026 guidance above $635M and strong margin growth.ADMA
Q4 202512 Apr 2026 - Q2 2024 revenue up 78% to $107.2M, net income $32.1M, guidance raised on ASCENIV growth.ADMA
Q2 20242 Feb 2026 - Directors and auditor were elected and ratified with strong support at the virtual meeting.ADMA
AGM 202431 Jan 2026 - ASCENIV's growth, margin expansion, and robust IP position signal a strong outlook.ADMA
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - Q3 2024 revenue up 78% and net income up 1,300%, with raised guidance for 2024–25.ADMA
Q3 202415 Jan 2026 - Yield enhancement and ASCENIV growth drive record revenue, margin expansion, and future potential.ADMA
44th Annual J.P. Morgan Healthcare Conference12 Jan 2026 - Patented immunotechnology and yield enhancements drive rapid revenue and earnings growth.ADMA
Corporate presentation12 Jan 2026